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Colitides remain an important yet less studied group of
inﬂammatory colon and rectal conditions with a range
of etiologies. This special issue includes a total of eight
papers examining several of these entities and related clinical
issues. Together, these papers highlight the breadth of these
disorders and their treatment, as well as some of the cutting-
edge issues related to our understanding of colitides and the
relationship of colorectal inﬂammation and disease.
Perhaps the most prominent iatrogenic colitide is
Clostridium diﬃcile colitis, an increasingly prevalent and
virulent condition. D. T. Rubin and colleagues conducted
a prospective open-label pilot study with rifaximin for
treatmentofClostridiumdiﬃcilecolitis,“Rifaximiniseﬀective
for the treatment of clostridium diﬃcile-associated diarrhea:
results of an open-label pilot study”. While Rifaximin demon-
strated eﬃcacy, this study highlights the need for further
prospective work to further assess its role in Clostridium
diﬃcile colitis management. N. E. Burkart et al. examined
the use of ﬂexible lower endoscopy as a diagnostic modality
to further deﬁne its utility and role in clinical care in
conjunction with clinical examination and diagnostic stool
studiesin“Indicationsandrelativeutilityoflowerendoscopyin
the management of clostridium diﬃcile infection”. In contrast,
P. Sinh and colleagues conducted a review of the literature
looking at the association and outcomes of Clostridium dif-
ﬁcile colitis and inﬂammatory bowel disease in “Clostridium
diﬃcile infection and inﬂammatory bowel disease: a review”.
Three of these studies examine fundamental biomedical
and diagnostic issues to colorectal inﬂammation. S. S. Yoon
and J. Sun review our current understanding of probiotics
and their role in anti-inﬂammatory pathways as shown in
“Probiotics, nuclear receptor signaling, and anti-inﬂammatory
pathways”. As our understanding colitides and inﬂamma-
tory pathways increase, these mechanisms become more
important. To better understand the link between colorectal
inﬂammation and malignancy, ˚ A. H˚ akansson and colleagues
developed a rat model to better delineate mechanisms
between chronic inﬂammation and transformation to malig-
nancy in a model for colorectal oncogenesis as shown in
“Colorectal oncogenesis and inﬂammation in a rat model
based on chronic inﬂammation due to cycling DSS treatments”.
Finally, K. Song et al. compared the use of a jumbo biopsy
forceps in colonic surveillance, demonstrating objective
evidence of improved sample size and potentially better
biopsy specimen quality for lower endoscopy “Novel jumbo
biopsy forceps for surveillance of inﬂammatory bowel disease: a
comparative retrospective assessment”.
T w oﬁ n a lp a p e r sf r o mW .B .G a e r t n e re ta l .“ Eosinophilic
colitis: university of minnesota experience and literature
review”andN.Doetal.“Radiationproctitis:currentstrategies
in management”, are detailed reviews on two less common
colitides. First, W. B. Gaertner performed a descriptive case
series and a review of eosinophilic colitis. N. Do and col-
leagues examined radiation proctitis, looking at the presen-
tation, signs and symptoms, and range of treatments for this2 Gastroenterology Research and Practice
entity. With the increasing shift towards radiation therapy
for prostate cancer and gynecological malignancies, the inci-
dence of radiation proctitis will likely continue to increase in
our elderly populations.
We hope that you will ﬁnd the content in this special
issue to be a valuable resource. Ultimately, we look forward
to bringing further attention to colitides within the greater
gastrointestinal, colorectal, and pathology communities and
to help inspire more investigators to further our understand-
ing of these important conditions.
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